Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.36 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | UBE2M | P61081 | 6/20 | 0.33 |
| ▸ | DCUN1D1 | Q96GG9 | 6/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240517 | 0.81 | UBE2M (0.41) | UBE2MDCUN1D1CCR5POLB | |
| SCHEMBL4235933 | 0.72 | CCR5 (0.54) | CCR5 | |
| SCHEMBL4245557 | 0.65 | UBE2M (0.48) | NPC1RAB9ALMNAL3MBTL1UBE2M | |
| SCHEMBL11318125 | 0.65 | HRH3 (0.40) | — | |
| SCHEMBL3762699 | 0.64 | MCHR1 (0.42) | CCR5 | |
| SCHEMBL3758110 | 0.64 | MCHR1 (0.42) | CCR5 | |
| SCHEMBL4240697 | 0.64 | CCR5 (0.54) | CCR5 | |
| SCHEMBL4248637 | 0.64 | CCR5 (0.54) | CCR5 | |
| SCHEMBL3749924 | 0.63 | CCR5 (0.65) | UBE2MDCUN1D1CCR5 | |
| SCHEMBL3757893 | 0.63 | CCR5 (0.50) | CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7491735-B2 | Chemokine receptor binding compounds | GENZYME CORPORATION (US) | 2009-02-17 | — | — | US | disclosed |
| US-20050277670-A1 | Chemokine receptor binding compounds | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277670-A1 | Chemokine receptor binding compounds | CCR5, CXCR3, CCL5 | NPC1 542/4885RAB9A 2043/4885TDP1 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.